Pictured: Zuria | Wilms Tumor
IMPROVING TREATMENTS AND SOLUTIONS
FOR LASTING IMPACT
Investing in Research to Fund a Cure
Funded research is the only way to create change in the outcomes for kids fighting rare pediatric cancer. The Beat Cancer giving program is the heart and soul of our organization, and 70% of our mission focus. It’s why we exist.
Funds from this program will be granted to Levine Children’s to help build the Isabella Santos Foundation Rare & Solid Tumor Program supporting rare pediatric cancer research. The ISF Rare and Solid Tumor Program opened in July 2020, with the arrival of the world-renowned cancer researcher, Dr. Giselle Sholler. The program rapidly grew to double solid tumor patient volume by the end of 2020, with patients from 20 countries.
Donors who give to the Beat Cancer program will help build a global rare childhood cancer program, fund much needed research for rare cancers, and ultimately create lasting impacts for kids fighting.
“The growth that has occurred in Charlotte for Pediatric Oncology has largely been due to the partnership and generosity of the Isabella Santos Foundation. The clinic will grow to become an international and national destination healthcare for children with solid tumors, brain cancers, and rare cancers. We will grow the precision medicine program, not only for children coming from across the globe but also for all children diagnosed here in Charlotte. In collaboration with the Levine Cancer Institute, we envision that every child diagnosed with a solid tumor here at Levine Children’s will have their tumor collected, banked, sequenced, and created into cell lines for research. This is so important for us to learn all that we can about each child to help them as well as to perform research in our laboratory to help us create better treatments and new clinical trials.” Dr. Sholler, Director, ISF Rare & Solid Tumor Program Director at Levine Children’s
Over the course of our foundation, ISF has donated $4,551,942 to Levine Children’s to help support pediatric cancer research.
“Isabella’s mom said during the hard times she was the only source of comfort for Isabella during treatment. It has stuck with me all these months and it rings so true for us as well. Having a hard time this last stay just reliving this whole year. ISF has helped me so much during this nightmare and I thank Isabella’s mom, and Isabella, for having the idea to help others. It’s made all the difference for our family.”
Pictured: Adam | Ewings Sarcoma (L), Brooklyn |Rhabdomyosarcoma (C), Dakota (L) Rhabdomyosarcoma
ISF RARE AND SOLID
TUMOR PROGRAM FOCUS
Donations to the Beat Cancer program will help fund the creation of a comprehensive team of providers and researchers uniquely positioned to advance care and research for rare and solid tumors. This program will serve nearly one-third of the 135 new cancer patients Levine Children’s Hospital sees each year and will allow the hospital to expand its clinical trials.
- Neuroblastoma: cancer found in immature nerve cells, mainly affecting young children and infants
- Osteosarcoma: most common type of bone cancer in children
- Ewing Sarcoma: type of cancer found in bones or soft tissue, often found in children/young adults ages 5-20
- Rhabdomyosarcoma: type of cancer in which malignant cells form in muscle tissue
- Wilm’s Tumor: type of childhood cancer found in the cells of the kidney
- Hepatoblastoma: a rare childhood cancer found in the liver
- Adrenal cortical carcinoma: a rare childhood cancer found in the adrenal gland
- Soft Tissue Sarcoma: a rare cancer that begins in soft tissue
- Desmond Tumor: a tumor that develops in the fibrous tissue
- Desmoplastic Small Round Blue Cell: a rare cancer usually found in the abdomen or pelvis
ISF FUNDED RESEARCH AND TREATMENTS
- Levine Children’s: ISF Rare & Solid Tumor Program. Oncologist Specializing in Sarcomas joins ISF Program
- Levine Children’s: ISF Rare & Solid Tumor Program. 3 Wish Society Funds Clinic Coordinator, Critical Role to Support Program
- Levine Children’s: ISF Rare & Solid Tumor Program. World-renowned cancer researcher, Dr. Giselle Sholler joins LCH Team
- Levine Children’s: MIBG Therapy Suite. Funded the design and construction of a leading-edge rare pediatric cancer treatment room at Levine Children’s Hospital, the Isabella Santos Foundation MIBG Suite. This treatment is known to be painless and extremely effective in the fight against neuroblastoma. Levine Children’s Hospital is 1 of 20 hospitals to have a MIBG Treatment room in the U.S. and the only location in the Charlotte region. The two-room MIBG suite provides targeted radiation to pediatric neuroblastoma patients with minimal side effects. This therapy impacts kids fighting cancer beyond the greater Charlotte region and will eventually expand to include adults with rare tumors.
- Levine Children’s: MIBG Therapy Comfort Baskets. As a child and family enter MIBG treatment they receive a gift basket specifically paid for 2018 ISF MIBG Ambassador fundraising efforts. Patients stay in the MIBG room 3-7 days after they receive their injection with parents/caregivers in the adjoining room. Baskets help bring a little comfort in their time away from their own home and can include gift cards, toys, movies, lovies, favorite snacks, games and more.
- Levine Children’s: Phase II Study for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults. Funded trial studying whether the drug combination of nab-paclitaxel and gemcitabine prevents the formation or growth of tumors in teens and young adults with sarcomas, which include Ewing’s sarcoma, osteogenic sarcoma, rhabdomyosarcoma, and non-rhabdomyosarcoma. The FDA has approved the use of this specific drug combination for the treatment of advanced pancreatic cancer in adults, and it is thought that this combination will also be effective in treating other cancers. (Launched by The Sunshine Project, in collaboration with Jeff Gordon Children’s Foundation & Joedance Film Festival).
- Levine Children’s: Developmental Therapeutics. Funded program which conducts, runs and underwrites all clinical trials for the rare and solid tumor team.